Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
about
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours.MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma
P2860
Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Alternating chemo-immunotherap ...... ents with metastatic melanoma.
@ast
Alternating chemo-immunotherap ...... ents with metastatic melanoma.
@en
type
label
Alternating chemo-immunotherap ...... ents with metastatic melanoma.
@ast
Alternating chemo-immunotherap ...... ents with metastatic melanoma.
@en
prefLabel
Alternating chemo-immunotherap ...... ents with metastatic melanoma.
@ast
Alternating chemo-immunotherap ...... ents with metastatic melanoma.
@en
P2093
P1433
P1476
Alternating chemo-immunotherap ...... ients with metastatic melanoma
@en
P2093
Bo Nilsson
Boel Ragnarsson-Olding
Eva Månsson-Brahme
Gunnar Wagenius
Johan Hansson
P304
P356
10.1097/01.CMR.0000205019.23612.A1
P407
P577
2006-08-01T00:00:00Z